Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, Pannunzio A, Gadner H, Schrappe M, Kamps WA, Bartram CR, van Dongen JJ, Panzer-Grümayer ER. Biondi A, et al. Leukemia. 2000 Nov;14(11):1939-43. doi: 10.1038/sj.leu.2401922. Leukemia. 2000. PMID: 11069029
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR. van Dongen JJ, et al. Among authors: biondi a. Lancet. 1998 Nov 28;352(9142):1731-8. doi: 10.1016/S0140-6736(98)04058-6. Lancet. 1998. PMID: 9848348
Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grümayer ER, Biondi A, San Miguel JF, van Dongen JJ. Pongers-Willemse MJ, et al. Among authors: biondi a. Leukemia. 1999 Jan;13(1):110-8. doi: 10.1038/sj.leu.2401245. Leukemia. 1999. PMID: 10049045
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.
Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM, Carroll A, Eden OB, Evans WE, Gadner H, Harbott J, Harms DO, Harrison CJ, Harrison PL, Heerema N, Janka-Schaub G, Kamps W, Masera G, Pullen J, Raimondi SC, Richards S, Riehm H, Sallan S, Sather H, Shuster J, Silverman LB, Valsecchi MG, Vilmer E, Zhou Y, Gaynon PS, Schrappe M. Pui CH, et al. Among authors: biondi a. Leukemia. 2003 Apr;17(4):700-6. doi: 10.1038/sj.leu.2402883. Leukemia. 2003. PMID: 12682627 Review.
1,498 results